We’ve seen tremendous progress in the field of cancer immunotherapy in recent years, and the potential now exists to improve on the benefits obtained with monotherapy by combining agents with complementary mechanisms of action.
More than 800 trials of immune-based combination therapies are underway; coupled with increasing opportunities for collaboration between the pharmaceutical and biotech industries, government and academia, the field is at an exciting juncture where the potential for novel therapeutic approaches has never been greater.
The SITC Combination Immunotherapies Task Force has convened to:
Journal for ImmunoTherapy of Cancer, February 2017
By summarizing the current status of combination immunotherapy, and addressing potential challenges in development and clinical implementation of combinatorial approaches, this paper provides evidence-based guidance to drive progress and improve on the clinical benefits obtained with single therapeutic agents. With greater understanding of the mechanisms of action of immunotherapy agents, and of the counter-defenses mounted by tumors, there is potential for novel combinations to increase the number of patients who respond to immunotherapy, the tolerability of treatment, and the duration of treatment response.
Patrick Ott, MD, PhD Dana-Farber Cancer Institute/Harvard Medical School
[Holbrook E. Kohrt, MD, PhD*] Stanford Cancer Institute
F. Stephen Hodi, MD Dana-Farber Cancer Institute
Howard L. Kaufman, MD, FACS Rutgers Cancer Institute of New Jersey
Drew M. Pardoll, MD, PhD Johns Hopkins University School of Medicine
Jon M. Wigginton, MD MacroGenics, Inc.
Jedd D. Wolchok, MD, PhD Memorial Sloan Kettering Cancer Center
*Holbrook Edwin Kidd Kohrt, MD, PhD (1977-2016) Dr. Kohrt had a significant impact on the field and brought his considerable scientific insights and incredible energy to every project. He was committed to the field of tumor immunology and immunotherapy and to the mission of SITC.
Immunotherapy@Brisbane 2017 Register online before Friday April 21! Final Program Released
EMBO KEYNOTE LECTURE Professor Sir Marc Feldmann Kennedy Institute of Rheumatology, University of Oxford, UK KEY SPEAKER Professor Shimon ...
This message was posted by a user wishing to remain anonymous Another Great Pittsburgher Dies - Philanthropist Henry Hillman led the renaissance of Pittsburgh's rebirth, a benefactor of the Hillman Cancer Center, an NCI Designated Cancer Center. http://www.post-gazette.com/local/city/2017/04/14/Philanthropist-Henry-Hillman-dies/stories/201704140181
Published April 11, 2017, in JAMA are the United States Preventative Services Task Force new recommendations for the surveillance of Prostate Cancer. The USPSTF recommends that the decision to have a DRE and prostate screening with PSA should be up ...
Immunotherapy@Brisbane 2017 Register online before Friday April 21! Leading International Speakers
EMBO KEYNOTE LECTURE Professor Sir Marc Feldmann Kennedy Institute of Rheumatology, University of Oxford, UK KEY SPEAKER ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org